Cell Source is engaged in the development and commercialization of proprietary technology which they license from the Weizmann Institute of Science. The Company is currently sponsoring both research and a clinical trial in at the University of Texas MD Anderson Cancer Center. Their principal operations are focused on developing innovative immunotherapy products focused on the effective treatment of blood cancers and nonmalignant blood disorders as well as the facilitation of safer and more accessible organ transplantation.